Skip to main content
. 2020 Sep 16;123(11):1656–1664. doi: 10.1038/s41416-020-01063-5

Fig. 1. Study flowchart and quantitative mass spectrometry.

Fig. 1

a Consort diagram; b Information on individual donor, sample pooling and TMT label; c High-throughput quantitative proteomics platform for cancer biomarker discovery; d Urinary protein with aberrant expression in gastric cancer patients. MS mass spectrometry, ELISA enzyme-linked immunosorbent assay, TMT tandem mass tag, GC gastric cancer, HC healthy control, IA + IB/Ctrl ratio of urinary protein in GC patients with stage IA or IB to that in HCs, II + III/Ctrl ratio of urinary protein in GC patients with stage II or III to that in HCs.